ABBVIE INC

AbbVie’s Q2 earnings reveal a pharma pivot: Humira sales dip yet oncology pipeline and Allergan integration drive growth, with macro and biosimilar risks highlighted.

First‑quarter 2026: Piramal Pharma shows steady revenue growth, higher EBITDA, and strong FDA compliance, positioning it for continued success in CDMO, generics, and consumer‑healthcare markets.

AbbVie’s newest biologic launches—Product A for ulcerative colitis and Product B for triple‑negative breast cancer—boost its pipeline and signal strong upside amid a booming antibody‑therapeutics market.

AbbVie’s upcoming earnings reveal how a new acquisition fuels R&D growth, regulatory strategy, and future cash flow amid Fed‑driven market volatility.

AbbVie’s $3.8 bn acquisition of Atai Beckley gives it a Breakthrough‑Therapy‑designated fast‑acting nasal spray for treatment‑resistant depression and social anxiety, expanding its CNS portfolio into a multi‑billion‑dollar psychedelic market.

AbbVie’s $10.9B Apogee acquisition boosts oncology, protects dividends, and opens GLP‑1 growth, but careful debt and integration management remain key.

AbbVie’s pivot to regenerative science—doubling R&D, launching AI‑driven skincare and flagship retail—boosts market share, mitigates patent cliffs, and opens M&A prospects.

Discover how AbbVie’s defensive profile withstands healthcare headwinds while investors seek growth in tech and energy—an insightful look at earnings stability.

AbbVie secures EU approval for a high‑response bispecific antibody in relapsed follicular lymphoma, boosting its oncology portfolio and investor appeal.

AbbVie’s expanding small‑molecule autoimmune pipeline—especially RINVOQ for SLE—blends steroid‑sparing data, pricing strategy, and M&A insight to target a $15 billion market while navigating patent cliffs.